Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 2: structure-activity relationships for substituted 2-Aryl-1-[N-(methyl)-N-(phenylsulfonyl)amino]-4-(piperidin-1-yl)butanes.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Bioorganic & Medicinal Chemistry Letters

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/S0960-894X(00)00639-9PMID 11206474
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Antagonists of the human CCR5 receptor as anti-HIV-1 agents. part 1: discovery and initial structure-activity relationships for 1 -amino-2-phenyl-4-(piperidin-1-yl)butanes.

  2001cited by this paper
• A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5.

  2000cited by this paper
• Chemokine Receptor Antagonists

  2000cited by this paper
• Discovery of novel, potent, and selective small-molecule CCR5 antagonists as anti-HIV-1 agents: synthesis and biological evaluation of anilide derivatives with a quaternary ammonium moiety.

  2000cited by this paper
• Current evidence and future directions for targeting HIV entry: therapeutic and prophylactic strategies.

  2000cited by this paper
• HIV-1 entry - an expanding portal for drug discovery.

  2000cited by this paper
• Human chemokines: an update.

  1997cited by this paper
• Host factors in the pathogenesis of HIV disease

  1997cited by this paper
• The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression

  1997cited by this paper
• Coreceptors--Implications for HIV Pathogenesis and Therapy

  1997cited by this paper
• Chemokine receptors and HIV-1: an attractive pair?

  1996cited by this paper
• Host factors and the pathogenesis of HIV-induced disease

  1996cited by this paper
• Chemokine Receptors and HIV-1: Minireview An Attractive Pair?

  1996cited by this paper
• Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection.

  1996cited by this paper
• Reductive Amination of Aldehydes and Ketones with Sodium Triacetoxyborohydride. Studies on Direct and Indirect Reductive Amination Procedures(1).

  1996cited by this paper
• In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors

  1995cited by this paper
• A facile synthesis of the novel neurokinin A antagonist SR 48968

  1993cited by this paper
• Palladium- and molybdenum-catalyzed hydrostannation of alkynes: a novel access to regio- and stereodefined vinylstannanes

  1990cited by this paper
• The Palladium‐Catalyzed Cross‐Coupling Reactions of Organotin Reagents with Organic Electrophiles [New Synthetic Methods (58)]

  1986cited by this paper
• Palladium catalyzed coupling of organotin reagents with organic electrophiles

  1985cited by this paper
• Chemoselective oxidation of sulfides to sulfones with potassium hydrogen persulfate

  1981cited by this paper

• Harnessing Electron Donor−Acceptor Complexes to Improve the Sustainability of the Enantioselective β‐Alkylation of Aromatic Enals

  2025cites this paper
• Ni/Photoredox-Catalyzed C(sp3)-C(sp3) Coupling between Aziridines and Acetals as Alcohol-Derived Alkyl Radical Precursors.

  2022cites this paper
• Discovery of Novel CCR5 Ligands as Anticolorectal Cancer Agents by Sequential Virtual Screening

  2021cites this paper
• The Duffy Antigen Receptor for Chemokines

  2020influential citation
• Recent updates for designing CCR5 antagonists as anti-retroviral agents.

  2018cites this paper
• Rh-Catalyzed Asymmetric Hydrogenation of 1,2-Dicyanoalkenes.

  2017cites this paper
• Medicinal chemistry of small molecule CCR5 antagonists for blocking HIV-1 entry: a review of structural evolution.

  2014cites this paper
• Design, Synthesis, and Optimization of Balanced Dual NK1/NK3 Receptor Antagonists.

  2014cites this paper
• Some case studies on application of “rm2” metrics for judging quality of quantitative structure–activity relationship predictions: Emphasis on scaling of response data

  2013cites this paper
• Balancing hERG affinity and absorption in the discovery of AZD5672, an orally active CCR5 antagonist for the treatment of rheumatoid arthritis.

  2012cites this paper
• Further exploring rm2 metrics for validation of QSPR models

  2011cites this paper
• Investigation of structure-activity relationship between chemical structure and CCR5 anti HIV-1 activity in a class of 1-[N-(Methyl)-N- (phenylsulfonyl)amino]-2-(phenyl)-4-[4-(substituted)piperidin-1-yl]butane derivatives: the electronic-topological approach.

  2011cites this paper
• CCR5 Antagonists in HIV

  2011cites this paper
• Small molecule antagonists of the chemokine receptor CCR5.

  2010cites this paper
• CC chemokine receptor small molecule antagonists in the treatment of rheumatoid arthritis and other diseases: a current view.

  2010cites this paper
• Rhodium- and Palladium-Catalyzed Hydroarylation of Propargylic Amines with Arylboronic Acids

  2010cites this paper
• Duffy antigen inhibitors: useful therapeutics for malaria?

  2010cites this paper
• On Two Novel Parameters for Validation of Predictive QSAR Models

  2009cites this paper
• Chemokine receptor antagonists: part 2

  2009cites this paper
• An arrestin‐dependent multi‐kinase signaling complex mediates MIP‐1β/CCL4 signaling and chemotaxis of primary human macrophages

  2009influential citation
• Predictive QSAR modeling of CCR5 antagonist piperidine derivatives using chemometric tools

  2009cites this paper
• Chapter 9 the duffy antigen receptor for chemokines.

  2009cites this paper
• QSAR Study on Novel CCR5 Receptor Antagonists: An Insight into the Structural Requirement for the HIV Co Receptor Antagonist Activity

  2008cites this paper
• Dioxirane Oxidations of Compounds other than Alkenes

  2008cites this paper
• Three-dimensional QSAR analyses of 1,3,4-trisubstituted pyrrolidine-based CCR5 receptor inhibitors.

  2008cites this paper
• Pharmacophore Model Generation Based on Pyrrolidine- and Butane-derived CCR5 Antagonists

  2007cites this paper
• Synthesis and Biological Evaluation of 1,3,3,4‐Tetrasubstituted Pyrrolidine CCR5 Receptor Antagonists. Discovery of a Potent and Orally Bioavailable Anti‐HIV Agent

  2007cites this paper
• QSAR modeling of CCR5 receptor antagonists using artificial neural network

  2007cites this paper
• An update in the development of HIV entry inhibitors.

  2007cites this paper
• Identification of nonpeptide CCR5 receptor agonists by structure-based virtual screening.

  2007cites this paper
• Thione-thiol rearrangement: miyazaki-newman-kwart rearrangement and others.

  2007cites this paper
• Identification and Characterization of a Potent, Selective Nonpeptide Agonist of the CC Chemokine Receptor CCR8

  2006cites this paper
• CCR5 antagonists: the answer to inflammatory disease?

  2006cites this paper
• Recent advances in combinatorial chemistry applied to development of anti-HIV drugs.

  2006cites this paper
• Novel, orally bioavailable gamma-aminoamide CC chemokine receptor 2 (CCR2) antagonists.

  2006cites this paper
• The HIV entry inhibitors revisited.

  2006cites this paper
• I want a new drug: G-protein-coupled receptors in drug development.

  2006cites this paper
• The clinical potential of chemokine receptor antagonists.

  2005cites this paper
• Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome.

  2005cites this paper
• Anti-MRSA agents: under investigation, in the exploratory phase and clinically available

  2005cites this paper
• Identification and Characterization of a Potent , Selective Nonpeptide Agonist of the CC Chemokine Receptor CCR 8

  2005cites this paper
• Synthesis and evaluation of CCR5 antagonists containing modified 4-piperidinyl-2-phenyl-1-(phenylsulfonylamino)-butane.

  2005cites this paper
• Small-molecule antagonists of CCR5 and CXCR4: a promising new class of anti-HIV-1 drugs.

  2004cites this paper
• Antiviral sulfonamide derivatives.

  2004cites this paper
• Orally bioavailable competitive CCR5 antagonists.

  2004cites this paper
• Chemokine receptor-directed agents as novel anti-HIV-1 therapies.

  2004cites this paper
• Three-dimensional quantitative structure-activity relationship analyses of piperidine-based CCR5 receptor antagonists.

  2004cites this paper
• Molecular docking and 3D QSAR studies on 1-amino-2-phenyl-4-(piperidin-1-yl)-butanes based on the structural modeling of human CCR5 receptor.

  2004cites this paper
• Development and evaluation of pharmacological agents targeting chemokine receptors.

  2003cites this paper
• Structural, chemical topological, electrotopological and electronic structure hypotheses.

  2003cites this paper
• Anticancer and antiviral sulfonamides.

  2003cites this paper
• Lead compounds discovered from libraries: part 2.

  2003cites this paper
• Unraveling the chemistry of chemokine receptor ligands.

  2003cites this paper
• Recent progress in discovery of small-molecule CCR5 chemokine receptor ligands as HIV-1 inhibitors.

  2003cites this paper
• Generation of predictive pharmacophore models for CCR5 antagonists: study with piperidine- and piperazine-based compounds as a new class of HIV-1 entry inhibitors.

  2003cites this paper
• Synthesis, structural characterization and in vitro antitumor activity of novel 6-chloro-1,1-dioxo-1,4,2-benzodithiazie derivatives.

  2003cites this paper
• Composes de cyclopropyle servant d'antagonistes de ccr5

  2003cites this paper
• Binding of 2-aryl-4-(piperidin-1-yl)butanamines and 1,3,4-trisubstituted pyrrolidines to human CCR5: a molecular modeling-guided mutagenesis study of the binding pocket.

  2003cites this paper
• Anti-HIV-1 peptides derived from partial amino acid sequences of CC-Chemokine RANTES

  2002cites this paper
• New therapeutics that modulate chemokine networks

  2002cites this paper
• Novel antiviral molecules

  2002cites this paper
• Anti-HIV-1 peptides derived from partial amino acid sequences of CC-chemokine RANTES. Regulated upon activation, normal T-cell expressed and secreted.

  2002cites this paper
• Synthesis, SAR, and biological evaluation of oximino-piperidino-piperidine amides. 1. Orally bioavailable CCR5 receptor antagonists with potent anti-HIV activity.

  2002cites this paper
• Potential new therapies for the treatment of HIV-1 infection.

  2002cites this paper
• Non-peptidic Chemokine Receptors Antagonists as Emerging Anti-HIV Agents

  2002cites this paper
• HIV entry inhibitors in clinical development.

  2002cites this paper
• Antagonists of the human CCR5 receptor as anti-HIV-1 agents. part 1: discovery and initial structure-activity relationships for 1 -amino-2-phenyl-4-(piperidin-1-yl)butanes.

  2001cites this paper
• Chemokine receptors--the next therapeutic target for HIV?

  2001cites this paper
• Piperazine-based CCR5 antagonists as HIV-1 inhibitors. I: 2(S)-methyl piperazine as a key pharmacophore element.

  2001cites this paper
• Antagonists of the Human CCR5 Receptor as Anti‐HIV‐1 Agents. Part 2. Structure—Activity Relationships for Substituted 2‐Aryl‐1‐[N‐(methyl)‐N‐(phenylsulfonyl)amino] ‐4‐(piperidin‐1‐yl)butanes.

  2001cites this paper
• Combinatorial synthesis of CCR5 antagonists.

  2001cites this paper
• 1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 1: discovery of the pyrrolidine scaffold and determination of its stereochemical requirements.

  2001cites this paper
• Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 3: a proposed pharmacophore model for 1-[N-(methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-[4-(substituted)piperidin-1-yl]butanes.

  2001cites this paper
• New antiretroviral agents: looking beyond protease and reverse transcriptase.

  2001cites this paper
• Discovery of 4-[(Z)-(4-bromophenyl)- (ethoxyimino)methyl]-1'-[(2,4-dimethyl-3- pyridinyl)carbonyl]-4'-methyl-1,4'- bipiperidine N-oxide (SCH 351125): an orally bioavailable human CCR5 antagonist for the treatment of HIV infection.

  2001cites this paper
• Design, synthesis, and SAR of heterocycle-containing antagonists of the human CCR5 receptor for the treatment of HIV-1 infection.

  2001cites this paper
• Novel antiviral molecules.

  2001cites this paper
• Discovery of human CCR5 antagonists containing hydantoins for the treatment of HIV-1 infection.

  2001cites this paper
• [Recommendations and prospects of antiretroviral therapy].

  2001cites this paper
• Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 4: synthesis and structure-activity relationships for 1-[N-(methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-(4-(N-(alkyl)-N-(benzyloxycarbonyl)amino)piperidin-1-yl)butanes.

  2001cites this paper
• 1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 2: lead optimization affording selective, orally bioavailable compounds with potent anti-HIV activity.

  2001cites this paper
• Fusion/entry inhibitors as therapies for HIV

  2001cites this paper